

**Amendments to the Specification:**

The following amendments to the specification are made with reference to the published US application (i.e., US Publication No. 2008/0274952) unless otherwise noted.

*Please amend the Title of the Invention as follows:*

Amylin Family Peptides and Methods for ~~Making and~~ Using Them for Treatment

*Please amend Paragraph No. 188 as follows:*

Figures 6A-6C ~~FIG. 6A-6B~~ depict the effect on triglycerides after 1 week (Fig. 6A), 2 weeks (Fig. 6B), and 3 weeks (Fig. 6C) ~~over time~~ by an exemplary compound (SEQ ID NO:137) of the invention.

*Please amend Paragraph No. 189 as follows:*

FIGS. 7A-7E depict the dose effect on triglycerides at baseline (Fig. 7A) and after 2 weeks (Fig. 7B), 4 weeks (Fig. 7C), 6 weeks (Fig. 7D), and 8 weeks (Fig. 7E) ~~over time~~ by an exemplary compound (SEQ ID NO:137) of the invention.

*Please amend Paragraph No. 190 as follows:*

FIG. 8A depicts the effect on ghrelin by amylin following the administration of a pentagastrin injection.

*Please amend Paragraph No. 191 as follows:*

FIGS. 8B-8C depict the comparative effect on ghrelin by saline and 30 µg/kg of amylin without a pentagastrin injection (Fig. 8B) and following a pentagastrin injection (Fig. 8C).

*Please amend Paragraph No. 192 as follows:*

FIG. 9A depicts the effect of plasma amylase, a marker on pancreatic function, by an exemplary compound (SEQ ID NO:137) of the invention.

*Please amend Paragraph No. 193 as follows:*

FIG. 9B depicts the effect of plasma lipase, a marker on pancreatic function, by an exemplary compound (SEQ ID NO:137) of the invention.

*Please amend Paragraph No. 196 as follows:*

FIG. 11A depicts the gastric mucosal protection ~~gastroprotective effect~~ of amylin.

*Please amend Paragraph No. 197 as follows:*

FIG. 11B depicts the gastric mucosal injury score ~~gastroprotective effect~~ of amylin.

*Please amend the Table in the originally-filed specification at Page 62 as follows:*

Table ~~2~~ X. EC<sub>50</sub> values (nM) for polypeptides

Compound	Amylin	Calcitonin	CGRP
1	0.028	0.029	2.342
2	0.047	0.052	33.988
3	0.023	0.020	0.490
4	0.035	0.019	8.500
5	0.022	0.018	2.600
6	0.030	nt	nt
7	0.057	nt	7.540
8	8.070	0.478	175.665
9	0.043	0.014	1.600

nt denotes not tested

*For the Table at pages 62-67 in the originally-filed specification, which was amended on August 10, 2006; please further amend as follows:*

Table 3

Compound (SEQ ID NO:)	30 min	60 min	120 min	180 min
1 (137)	-58	-46	-33	-22
2 (136)	-58	-54	-52	nt
3 (135)	-58	-52	-37	-33
4 (40)	-42	-31	-35	-30
5 (43)	-66	-53	-29	-27
6	-48	-45	-23	nt
7 (134)	-60	-52	-23	nt
8	-6	-15	-25	-28
9 (71)	-80	-64	-43	nt
10	-19	-20	-35	nt
11 (41)	-52	-47	-38	-35
12 (42)	-43	-39	-37	-32
13 (44)	-40	-33	-25	-24
14 (45)	-52	-36	-28	-33
15 (46)	-67	-59	-37	-30
16	-26	-29	-30	-27
17 (47)	-42	-30	-30	-25
18 (48)	-2	-7	-16	-21
19 (49)	-25	-25	-35	-31
20 (50)	-9	-21	-30	-31

Compound (SEQ ID NO:)	30 min	60 min	120 min	180 min
21 (51)	9	-5	-18	-18
22 (52)	-11	-20	-31	-30
23 (53)	8	0	-19	-12
24 (54)	-40	-34	-35	-35
25 (55)	-29	-34	-45	nt
26 (56)	-29	-36	-47	nt
27 (57)	-12	-11	-32	nt
28 (58)	-8	-16	-28	nt
29 (59)	4	-1	-25	nt
30 (60)	-1	-2	-19	nt
31 (61)	-11	-18	-23	nt
32 (62)	-15	-21	-31	nt
33	-7	-10	-15	nt
34	-11	-6	-16	nt
35 (63)	-20	-16	-18	nt
36 (64)	-34	-22	-24	-25
37 (65)	-3	-2	-16	nt
38	-24	-13	-8	nt
39 (66)	7	-14	-23	nt
40	-11	-5	-2	nt
41	-4	-9	-12	nt
42	-11	-18	-32	nt
43	-4	-7	-18	nt

Compound (SEQ ID NO:)	30 min	60 min	120 min	180 min
44 (69)	-6	-13	-25	nt
45	-13	-7	-3	nt
46	-6	-11	-16	nt
47 (70)	-5	-13	-27	nt
48 (72)	-54	-51	-36	nt
49 (73)	-33	-26	-25	nt
50 (74)	-70	-62	-48	nt
51 (75)	-44	-39	-35	nt
52 (76)	-29	-24	-23	nt
53 (77)	-92	-89	-36	nt
54	1	-4	-10	nt
55	9	-5	-12	nt
56	4	-13	-16	nt
57 (78)	-18	-24	-23	nt
58 (79)	-62	-51	-29	nt
59 (80)	-81	-77	-50	nt
60 (81)	-43	-40	-26	nt
61 (82)	-23	-27	-32	nt
62 (83)	-14	-22	-38	nt
63 (84)	-19	-22	-28	nt
64 (85)	-65	-58	-44	nt
65 (86)	-33	-29	-32	nt
66 (87)	-13	-15	-28	nt

Compound (SEQ ID NO:)	30 min	60 min	120 min	180 min
67	-10	-11	-12	nt
68 (88)	-10	-13	-21	nt
69 (89)	-29	-31	-45	nt
70 (90)	-76	-64	-47	nt
71 (91)	-7	-13	-22	-18
72 (92)	0	-8	-13	-19
73 (93)	-51	-31	-23	-28
74 (94)	-42	-32	-31	nt
75 (95)	-60	-52	-38	nt
76 (96)	-25	-29	-40	nt
77 (97)	-46	-43	-44	nt
78 (98)	-57	-44	-44	nt
79 (99)	-49	-40	-33	nt
80 (100)	-32	-28	-22	nt
81 (101)	-28	-24	-33	nt
82 (102)	-7	-13	-16	-19
83 (103)	-7	-13	-22	-12
84 (104)	-53	-40	-20	nt
85 (105)	3	-16	-16	nt
86 (106)	-44	-26	-16	nt
87 (107)	-43	-32	-21	nt
88 (108)	-64	-61	-39	-22
89 (109)	-6	-13	-22	-20

Compound (SEQ ID NO:)	30 min	60 min	120 min	180 min
90 (110)	-55	-41	-24	-15
91 (111)	-59	-47	-26	-24
92 (112)	-31	-29	-30	-27
93 (113)	-43	-30	-27	-29
94 (114)	-62	-42	-36	-31
95 (115)	-81	-69	-34	-31
96 (116)	-49	-38	-19	-23
97 (117)	-78	-76	-60	-40
98	-18	-13	-5	-1
99 (118)	-57	-55	-50	nt
100 (119)	-60	-52	-41	nt
101 (120) (110)	-52	-48	-35	nt
102 (121)	-58	-53	-45	nt
103 (122)	-50	-44	-30	nt
104 (123)	-69	-67	-54	nt
105 (124)	-83	-82	-52	nt
106 (125)	-58	-54	-39	nt
107 (126)	-84	-78	-47	nt
108 (127)	-70	-66	-38	nt
109 (128)	-61	-54	-43	nt
110 (129)	-80	-72	-59	nt
111 (130)	-39	-37	-32	nt
112 (131)	-62	-65	-50	nt

Compound (SEQ ID NO:)	30 min	60 min	120 min	180 min
113 (132)	-79	-86	-55	nt
114 (133)	-17	-20	-25	nt
115	6	-3	-25	-25
116	5	5	3	nt
117	-13	-11	-3	nt
118	-4	0	13	nt
119	6	-8	-11	nt
120	-3	1	-6	-7
121	5	2	-1	3
122	-6	-12	-23	-21
123	1	-13	-17	-13
124	4	-4	-15	-16
125	10	-1	-6	nt
126	5	-10	-20	nt
127	-5	-14	-12	-12

nd=not done



*Please amend the Table in the originally-filed specification at Page 68 as follows:*

Table 4 X Body weight loss after administration of exemplary compounds of the invention

<i>Compound</i>	<i>Week 1</i>	<i>Week 2</i>
Compound 1	8.3*	10.5*
Compound 2	9.8*	9.4*
Compound 3	5.9*	6.7*
Compound 4	6.8*	9.2*
Compound 5	8.6*	11.3*
Compound 6	2.9*	3.8*
Compound 7	10.0*	11.4*
Compound 8	2.3	2.5
Compound 9	4.9*	4.9*

\*P<0.05 compared to controls